BlackRock, Inc. 13D and 13G filings for Fulcrum Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
4,032,876 7.500% |
-1,542,440 (-27.67%) |
Filing |
| 2024-12-06 4:28 pm Sale |
2024-11-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
5,575,316 10.300% |
-131,304 (-2.30%) |
Filing |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
5,706,620 9.100% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
5,706,620 9.100% |
4,192,195 (+276.82%) |
Filing |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
1,514,425 2.500% |
-1,754,566 (-53.67%) |
Filing |
| 2023-02-01 4:54 pm Purchase |
2022-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
3,268,991 6.300% |
1,060,913 (+48.05%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
BlackRock Inc. BLK |
2,208,078 5.400% |
2,208,078 (New Position) |
Filing |